A Randomised, Double-blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Two Doses of Inhaled CHF6001 DPI After 9 Days of Treatment in Adult Patients With Asthma.

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Two Doses of Inhaled CHF6001 DPI After 9 Days of Treatment in Adult Patients With Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs CHF 6001 (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Sep 2012 Planned End Date changed to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top